Targeting Hematological Malignancies With Autologous and Allogeneic Cell Therapies

Video

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

“We want to explore opportunities in the allogeneic field. And of course, that's what I think a lot of companies are currently trying and there's a lot of excitement about it. So how do we move from this autologous treatment to an off the shelf treatment, which obviously would be better in terms of treatment cost and also in terms of time to treatment... we have a very promising early phase development in solid tumors.”

Tessa Therapeutics is targeting both hematological malignancies and solid tumors, with its autologous chimeric antigen receptor (CAR) T-cell therapy programs as well as allogeneic virus-specific T-cell therapies. The company recently dosed the first patient with relapsed/refractory classical Hodgkin lymphoma (cHL) in the phase 1b ACTION clinical trial (NCT05352828) of TT11, an autologous CD30-targeted chimeric antigen receptor T-cell (CAR-T) therapy being developed as a second-line treatment in combination with nivolumab in August 2022. TT11 is also being evaluated as a monotherapy in later lines of treatment for cHL in the phase 2 CHARIOT trial (NCT04268706).

CGTLive spoke with Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, to learn more about the company and its technologies. He discussed Tessa’s current cell therapy programs as well as allogeneic programs for solid tumors in early development. He also touched on upcoming milestones for the company in 2023.

REFERENCE
Tessa Therapeutics doses first patient in phase 1b clinical trial investigating TT11 in combination with nivolumab for t he treatment of relapsed/refractory classical Hodgkin lymphoma (cHL). News release. Tessa Therapeutics. August 17, 2022. https://www.tessacell.com/2022/08/17/tessa-therapeutics-doses-first-patient-in-phase-1b-clinical-trial-investigating-tt11-in-combination-with-nivolumab-for-the-treatment-of-relapsed-refractory-classical-hodgkin-lymphoma-chl/
Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.